Research has found that variability in stuttering is addressed and treated differently by speech language pathologists and generalists, and that more real-life experience for trainees can help reduce the gap.
Sarah* is 34, works in administration, and has spent two years without a diagnosis. Her symptoms began with cognitive episodes — words vanishing from her screen mid-sentence and memory lapses — followed by functional seizures and right-sided weakness requiring emergency department care. CT scans and an MRI were unremarkable. She was variously labelled with migraine and anxiety and referred back to her GP. Patients like Sarah are common, yet our health system offers no clear pathway for their care.
Researchers are uncovering important patterns in post-stroke cognitive impairment which suggest that factors outside stroke location contribute to the specific combination of deficits expressed in individuals.
MS Australia’s 2025 Research and Advocacy Priorities Survey captures what matters most to Australians affected by multiple sclerosis. Drawing on insights from more than 2 000 participants, it highlights evolving research and advocacy priorities, and provides a community‑driven roadmap to guide research investment, policy reform and clinical practice nationwide.
A recent paper co-authored by 39 leading scientists names the Polyvagal Theory (PVT) ‘untenable.’ It’s the work of two decades, with agreement from experts in wide-ranging fields. But some in the psychological community are hesitant to let PVT go.
Health care must be a priority for this federal election. And within health care, neurological conditions must be prioritised.
A total of 80 consensus recommendations have been developed to guide best-practice management of multiple sclerosis in Australia and New Zealand.
Researchers at Monash University have isolated the electrical activity of single neurons from recordings of human vagus nerves and identified a subset that have cardiovascular function.
Parkinson’s disease neurologists and advocates are urging the Australian Pesticides and Veterinary Medicine Authority (APVMA) to ban the common herbicide paraquat, citing compelling evidence linking its use to the development of Parkinson’s disease.
